Reshaping the HIV treatment and prevention landscape

Vaccines and Specialty Medicines priorities in key markets: US Specialty Care driving 60% of US sales in 2026 Illustrative Vaccines 2017 Specialty Medicines General Medicines 2021 2026 2021-26 growth priorities - - - - Shingrix recovery and growth Cabenuva & Cab PrEP launches Maintain Nucala and Benlysta leadership Zejula PARPi leadership in OC Blenrep expansion to earlier lines Grow Trelegy in COPD and asthma Launch readiness for daprodustat, otilimab, RSV and Men ABCWY gsk 38

View entire presentation